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Recommendations for laboratories to report incidental findings from genomic tests have stimulated interest in such results.
In order to investigate the criteria and processes for assigning the pathogenicity of specific variants and to estimate the
frequency of such incidental findings in patients of European and African ancestry, we classified potentially actionable
pathogenic single-nucleotide variants (SNVs) in all 4300 European- and 2203 African-ancestry participants sequenced by
the NHLBI Exome Sequencing Project (ESP). We considered 112 gene-disease pairs selected by an expert panel as associated
with medically actionable genetic disorders that may be undiagnosed in adults. The resulting classifications were compared
to classifications from other clinical and research genetic testing laboratories, as well as with in silico pathogenicity scores.
Among European-ancestry participants, 30 of 4300 (0.7%) had a pathogenic SNV and six (0.1%) had a disruptive variant
that was expected to be pathogenic, whereas 52 (1.2%) had likely pathogenic SNVs. For African-ancestry participants, six of
2203 (0.3%) had a pathogenic SNV and six (0.3%) had an expected pathogenic disruptive variant, whereas 13 (0.6%) had
likely pathogenic SNVs. Genomic Evolutionary Rate Profiling mammalian conservation score and the Combined Anno-
tation Dependent Depletion summary score of conservation, substitution, regulation, and other evidence were compared
across pathogenicity assignments and appear to have utility in variant classification. This work provides a refined estimate of
the burden of adult onset, medically actionable incidental findings expected from exome sequencing, highlights challenges in
variant classification, and demonstrates the need for a better curated variant interpretation knowledge base.
[Supplemental material is available for this article.]
Whole genome and exome tests are increasingly applied in clinical
medicine. The American College of Medical Genetics and Geno-
mics (ACMG) has recommended identification and return of
incidental findings (IFs) from a minimum set of 56 actionable
genes when a genomic test is performed (Green et al. 2013), unless
patients opt out (American College of Medical Genetics and Ge-
nomics 2014). Some clinical laboratories return a broader set of IFs.
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However, there are limited data on frequency of such actionable
pathogenic variants, and a standardized level of evidence for de-
termining the pathogenicity of these variants has not been iden-
tified. We previously reviewed the primary literature for possible
actionable, high penetrance pathogenic single-nucleotide variants
(SNVs) in 114 genes in 500 European- and 500 African-ancestry
participants randomly selected from the NHLBI Exome Sequenc-
ing Project (ESP) and posted on the exome variant server (EVS;
http://evs.gs.washington.edu/EVS/) (Dorschner et al. 2013).Wenow
extend these analyses to the 5503 additional participants in the ESP
and revise from 114 to 112 genes associated with medically action-
able genetic disorders thatmay remain undiagnosed in adults. These
data give amore precise estimate of the frequency of such actionable
findings in individuals of European or African ancestry. Such an es-
timate will allow a better understanding of the implications, in-
cluding cost, of recommendations to return IFs from genomic tests.
Lack of consensus criteria for pathogenicity classification of
variants is an ongoing issue in genomicmedicine. It is common for
clinicians to disagree with classifications from clinical laboratories.
Therefore, we compare the results of our variant classification
system to the classification of these variants by different clinical
and research laboratories. A goal of these analyses is to investigate
consistency in variant classification using criteria from different
classification systems and to understand the features of these ap-
proaches that lead to discrepant pathogenicity assignments.
Results
Characteristics of the variants reviewed
Variants in 112 genes pairedwithmedically actionable phenotypes of
interest were reviewed in the 6503 participants from the NHLBI ESP.
The variant classification criteria and categories are presented in Table
1A and Table 1B, respectively. There were 615 distinct variants an-
notated in the Human Gene Mutation Database (HGMD) as disease
causing in these 6503 participants’ exomes: 224were identified in the
original 1000 participants (500 European ancestry and 500 African
ancestry) inDorschner et al. (2013) and 391 additional variants in the
remaining 5503 (4300 European-ancestry and 2203 African-ancestry)
participants. This is attributable to the most common variants being
identified in the first set analyzed, leaving fewer novel variants in the
second set. Of the 615 unique variants, 116 (18.9%) variants had
a minor allele frequency (MAF) greater than the allowable estimated
disorder allele frequency and were not compatible with a highly
penetrant disorder. On review of the literature, none of these 116
variantswas classified aspathogenic or likelypathogenic by reviewers.
Most variants were observed more than once. Of the 599
variants in genes associated with dominant disorders, 44% (261/
599) were seen only once. These singleton variants represented 51
(79.7%) of the 64 pathogenic or likely pathogenic variants in genes
associated with dominant disorders. This frequency represented
a significant excess of rare pathogenic variants relative to those
variants observed more than once (P = 4.6 3 109). The distribu-
tion of the MAF of these variants for disorders inherited in an au-
tosomal dominant pattern by classification is summarized in Table
2. The highest ancestry-specificMAF is a strong predictor of variant
classification, excluding the likely benign class and variants in
genes associated with recessive disorders (P = 0.01).
Variants classified as pathogenic or likely pathogenic
We used stringent criteria to classify variants as pathogenic or
likely pathogenic given that we are addressing potential IFs. The
details of the variant classification framework and review process
are described inMethods. Variant classifications are summarized in
Table 3 and the classification for each variant is given in Supple-
mental Table 1. We found 32 unique variants in 16 genes in all
6503 participants when considering the ‘‘pathogenic’’ variants
from those annotated as disease causing in HGMD. The genes with
these variants are summarized in Table 4 and the individual vari-
ants are listed in Supplemental Table 2. Pathogenic variants were
found in 36/6503 (0.6%) of the ESP participants. Thirty-one par-
ticipants had pathogenic variants in ACMG genes, whereas five
had pathogenic variants in non-ACMG genes. Note that four of
these 36 individuals were compound heterozygotes for two path-
ogenic variants assumed to be in trans in genes associated with
disorders inherited in an autosomal recessive pattern. None of
these 36 participants had more than one pathogenic or likely
pathogenic variants in genes associated with dominant disorders.
One individual was heterozygous for a pathogenic variant in
ATP7B; however, this individual is not counted in the total number
of participants with pathogenic results because carrier status was
not considered reportable. Pathogenic variants were found in
30/4300 (0.7%) European-ancestry participants versus 6/2203
(0.3%) African-ancestry participants. No pathogenic variants were
found in the 208 participants of Ashkenazi Jewish ancestry.
Table 1. Variant classification criteriaa,b and variant classification
categories
(A) Variant classification criteria
Allele frequency of variant A1. Below cutoffc
A2. Above cutoff
Segregationd B1. In $2 unrelated families
B2. In one family
B3. No segregation studies
Number of affected
unrelated individuals
C1. Identified in $3 unrelated affected
individualse or a significant difference
in cases versus controlsf
C2. Identified in <3 unrelated affected
individuals
De novo events in a triog D1. $1 event
D2. No events
Function E1. Protein truncationh where protein
truncation is known to cause disorder
Other F1. Seen only in combination with a
known pathogenic variant for a
dominant disorder








A1 plus A1 plus A1 plus A2 +/or F1
B1 B2 B3
or B2 + C1 or C1 or C2
or B2 + D1 or D1 or D2
or A1 + E1
aCautiously interpret functional evidence for all variant categories.
bClassify based on amino acid change, regardless of nucleotide change.
cBased on disorder frequency and inheritance pattern.
dDefined as probability of consistent sharing in the family of #1/16.
eIf plausible based on frequency of disorder.
fFor common variants.
gMutation identified as de novo dominant in an affected offspring of un-
affected parents (with known paternity).




We found 38 unique variants in 23 geneswhen evaluating the
‘‘likely pathogenic’’ variants from those annotated as disease
causing in HGMD for all 6503 participants. The genes with these
variants are summarized in Table 4, and the individual variants are
listed in Supplemental Table 1. A total of 65/6503 (1.0%) ESP
participants had likely pathogenic mutations. Three individuals
were compound heterozygous for one pathogenic and one likely
pathogenic variant assumed to be in trans in genes associated with
disorders inherited in an autosomal recessive pattern. A total of 53/
65 (81.5%) had likely pathogenic variants in genes for which
pathogenic variants are recommended for return by the ACMG
report. Of these 65 participants with likely pathogenic variants, 52
(80%) were of European ancestry and 13 (20%) of African ancestry.
Four of the European ancestry individuals with likely pathogenic
variants also had Ashkenazi ancestry.
Variants classified as expected pathogenic
‘‘Disruptive’’ expected pathogenic variants were defined as trun-
cating and missplice-causing variants in the EVS that are not
identified by HGMD as disease causing. The classification process
for these variants included identifying those within the part of the
transcript that likely lead to nonsense-mediated mRNA decay and
investigating if truncating and missplice-causing variants are
known to cause the associated phenotype of interest. There were
11 of these expected ‘‘disruptive’’ variants that were not listed in
HGMD as disease-causing variants (Supplemental Table 3). There
was no significant difference in distribution of expected patho-
genic variants between ancestry groups; of the 12 participants with
such variants, six were in the African-ancestry group and six in the
European-ancestry group (P = 0.12), although power was limited.
A flowchart summarizing the number of HGMD disease-
causing variants and non-HGMD expected disruptive variants
reviewed, and the classifications of these variants in ACMG and
non-ACMG genes, is presented in Figure 1.
Ancestry differences in identification of pathogenic or likely
pathogenic variants
The number of pathogenic or likely pathogenic variants in in-
dividuals of African and European ancestry was compared. Among
all 6503 subjects, the participants of African ancestry had fewer
pathogenic or likely pathogenic variants annotated in HGMD
(Table 3) than those of European ancestry, consistent with the
prior analysis of 1000 participants. Only 19 (18.8%) of the 101
participants with likely pathogenic or pathogenic variants were
in individuals of African ancestry, again significantly less than
the proportion (2203/6503, 33.8%) that would be expected at
random under the null hypothesis (binomial test P = 0.0004).
This result replicates the previously reported deficit of HGMD
derived pathogenic or likely pathogenic variants among African-
ancestry individuals.
Median time and concordance in double review of variants
The time spent for the literature review and categorization step for
each HGMD disease-causing variant by the initial reviewer was
recorded. The median recorded time was 37 min (range: 1–175
min). This time did not include the time to generate the list of
potential variants, collect the references, or resolve variants by
secondary review.
Several quality control exercises were undertaken including
the examination of 156 of the 615 disease-causing HGMD variants
by a second reviewer. In addition, all variants initially classified as
pathogenic or likely pathogenic (79) were reanalyzed by an expe-
rienced reviewer. Of the 156 variants that were initially double
reviewed, 83 (53%) of the classifications were discrepant. Of the 79
variants initially classified as pathogenic and likely pathogenic
that underwent blinded expert review, 56% (44/79) were reclassi-
fied. Nearly all of these reclassifications (42/44) were from the
pathogenic or likely pathogenic classification to the variant of
uncertain significance (VUS) classification. A repeated error was
counting EVS participants as a person who is affected with the
disorder and has the variant, even though the phenotypes of those
participants were unknown. This was compounded when papers
had reported the variants in EVS without relevant phenotype in-
formation for specific disorders (e.g., cardiomyopathy). As a result,
all articles summarizing EVS data were identified, and the named
variants were re-reviewed to be sure that papers referring to EVS
data were not included in the calculation of the number of af-
fecteds carrying the variant of interest. Geneticists of all experience
levels made classification errors.
Variant classifications were com-
pared with those collected through the
Sharing Clinical Reports Project (SCRP).
There was complete agreement (45/45)
between classifications from the SCRP and
those made by our reviewers. The classifi-
cation of variants reviewed by both this
project and the Partners Laboratory for
Molecular Medicine (LMM) were also
compared and agreement was high (97/
99, 98%) (Supplemental Table 4). A sum-
mary of the evidence supporting the two
Table 2. Highest ancestry-specific minor allele frequency (MAF) in EVS of HGMD disease-causing variants in dominant genes by variant
classification
Pathogenic Likely pathogenic Uncertain significance Likely benign
N 29 34 395 135
Mean (range) 0.015 (0.012–0.035%) 0.023 (0.012–0.068%) 0.075 (0.012–1.037%) 0.206 (0.012–1.407%)
Table 3. Summary of number of participants with variant classifications in 112 genes and the
56 ACMG genes
European ancestry
N = 4300 (ACMG)a
African ancestry
N = 2203 (ACMG)
Pathogenic variants from HGMD 30 (0.7%) [26 (0.6%)] 6 (0.3%) [5 (0.2%)]
Likely pathogenic variants from HGMD 52 (1.2%) [41 (1.0%)] 13 (0.6%) [12 (0.5%)]
Novel disruptive variants 6 (0.1%) [3 (0.07%)] 6 (0.3%) [6 (0.3%)]
Total 88 (2.0%) [70 (1.67%)] 25 (1.1%) [23 (1.0%)]
aThe second, square-bracketed value indicates the summary considering only the 56 ACMG gene-
disease pairs versus the 112 considered by authors.
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different classifications is also presented. These few discrep-
ancies are due, in part, to differences in classification criteria,
including Partners LLM’s inclusion of in silico predictions and
use of functional data as supporting pieces of evidence, as well
as reducing the significance of a variant when it has been
reported in a person with an alternate explanation of the dis-
order. These results demonstrate that discrepant variant classi-
fications may result even when the same public resources are
used when different types of evidence are given different
weights.
In addition, six variants were randomly selected within
groups of varying pathogenicity assignments and were classified
blindly by five research and clinical laboratories within the
Clinical Sequencing Exploratory Research (CSER) consortium
(http://www.genome.gov/27546194) according to their routine
laboratory procedures. These variants along with each labo-
ratory’s classification are listed in Table 5. Complete agreement
was attained only for the truncating variant; in contrast, for one
variant, classification ranged from pathogenic to variant of un-
certain significance. One laboratory appeared to have a lower
threshold for calling variants likely pathogenic than the others.
This difference in threshold raises concern for the consistency of
variant assignments across laboratories. An investigation of the
basis for discrepant classifications (data not shown) found that
discrepancies appeared to result from differences in how coseg-
regation was used, how functional and in silico evidence were
weighted, as well as in differences in resources used among
reviewers.
Association of in silico pathogenicity scores with pathogenicity
assignment
To address the utility of incorporating in silico pathogenicity
scores into the interpretation of variants, Genomic Evolutionary
Rate Profiling (GERP) and Combined Annotation Dependent De-
pletion (CADD) scores were compared across pathogenicity as-
signments (Table 6; Fig. 2). As previously noted, these scores were
not used in our classifications. High CADD and GERP scores were
found in all pathogenicity categories. Low and negative scores
were seenmore often in the likely benign class, while all variants in
the pathogenic class had GERP $ 2.95 and CADD $ 12.37.
Discussion
We have analyzed exomes of 6503 ESP participants for variants in
112 medically actionable genes. We found that some 2.0% of
adults of European ancestry and 1.1% of adults of African ancestry
can be expected to have actionable highly penetrant pathogenic
(including novel expected pathogenic) or likely pathogenic single-
nucleotide variants (SNVs). If we analyze only pathogenic variants
in the subset of genes that are included in the ACMG recom-
mendations for reporting of IFs (Green et al. 2013), the proportion
of individuals with returned IFs would be 0.7% in European-
ancestry participants and 0.5% in African-ancestry participants.
Our classification of these reviewed variants is expected to be
useful to clinical geneticists who commonly consult the EVS to
determine allele frequencies and when evaluating SNV pathoge-









BRCA1 or BRCA2 Breast/ovarian cancer 7 (7) 0 (0) 3 (3)
MSH6, PMS2, CHD1 GI cancer 4 (4) 1 (2) 2 (3)




Cardiomyopathy 4 (4) 14 (24) 2 (2)
RYR1 Malignant hyperthermia 4 (5) 1 (2) 0 (0)
KCNQ1, SCN5A Arrhythmia 1 (1) 3 (7) 0 (0)
RET Multiple endocrine neoplasia 1 (1) 0 (0) 0 (0)
TP53 Li-Fraumeni syndrome 1 (1) 2 (6) 0 (0)
DSC2, DSP Arrhythmogenic right
ventricular dysplasia
0 (0) 0 (0) 2 (2)
ACMG gene total 26 (29) 28 (53) 9 (10)
Non-ACMG genes
SERPINA1 Lung disease 2 (4a) 2 (3b) 0 (0)
PROC Protein C deficiency 1 (1) 2 (2) 0 (0)
PROS Protein S deficiency 0 (0) 0 (0) 1 (1)
ATP7B Wilson disease 1 (3c) 0 (0) 0 (0)
ENG, ACVRL1 Hereditary hemorrhagic
telangiectasia
1 (1) 1 (1) 0 (0)
FLCN Birt-Hogg-Dube 1 (1) 0 (0) 0 (0)
DMD Cardiomyopathy 0 (0) 1 (1) 0 (0)
KCNE1, KCNE2 Arrhythmia 0 (0) 2 (4) 0 (0)
SLC7A9 Cystinuria 0 (0) 1 (1c) 0 (0)
HMBS Porphyria 0 1 (1) 0 (0)
PTCH1 Basal cell nevus syndrome 0 (0) 0 (0) 1 (1)
Non-ACMG gene total 6 (7) 10 (12) 2 (2)
Grand total 32 (36) 38 (65) 11 (12)
aParticipant was compound heterozygote for two pathogenic variants.
bParticipant was compound heterozygote for one pathogenic variant and one likely pathogenic variant.




nicity. Based on the few differences in our classification and those
of Partners LMM,wemay be overcalling variants that are truly VUS
as likely pathogenic, as all of our differences are of this type. These
data are based on contemporary variant databases and such data-
bases are expected to include more classified variants over time.
Our variant classifications in Supplemental Table 1 are annotated
for which variants might be moved to a lower class if the base
position’s evolutionary conservation were incorporated into our
criteria. The use of conservationwould not affect the classifications
of any variants we classified as pathogenic.
Notably, these data do not suggest that <2% of individuals
will have abnormal genomic tests. Abnormal tests will also include
results for the primary indication, copy number variants, and
nonactionable disorders, none of which are considered in these
analyses. Further, we consider only high penetrance variants. The
results presented here reflect expected actionable IFs from SNVs
identified in exome sequencing.
This report is consistent with the proportion of participants
with pathogenic variants estimated for the non-Ashkenazi ancestry
participants in ClinSeq, despite differences in criteria for classifica-
tion. Considering 37 cancer risk genes, ClinSeq found four of
475 non-Ashkenazi (0.8%) participants had pathogenic variants,
whereas four of 97 participants of Ashke-
nazi ancestry (4.1%) did (Johnston et al.
2012); seven of these eight variants were
in BRCA1 or BRCA2. We considered 34 of
the 37 genes included by ClinSeq. ClinSeq
reported no pathogenic variants in the
remaining three genes: RB1, WT1, and
CDKN2A. Examining only those 34 genes
in the non-Ashkenazi ancestry group
separately, our proportion of participants
with pathogenic variants did not differ
with those of ClinSeq (both P = 0.78). Al-
ternatively, for those of Ashkenazi ancestry,
our data was not comparable to that of
ClinSeq due to our lack of insertion and
deletion (indel) data. BRCA1 or BRCA2
founder mutations, all indels, have been
reported to be found in 2.4% of 3742 Ash-
kenazi ancestrywomen (Hartge et al. 1999).
The proportion of participants with
pathogenic and likely pathogenic vari-
ants reported here is slightly lower than
that reported in our previous work with
1000 EVS samples (Dorschner et al.
2013). The revised estimates are likely due
to (1) imprecision related to the smaller
sample size, and (2) the absence of double review of all pathogenic
and likely pathogenic variants in the original paper. After correc-
tion following double review, 2.4% of the original 500 European-
ancestry participants and 0.8%of the original 500 African-ancestry
participants had pathogenic or likely pathogenic SNVs.
The estimates reported here of ;2.0% of adults of European
ancestry and 1.1% of adults of African ancestry having high pen-
etrance actionable variants are substantially different from the
estimate of 5% of participants (14 variants in 27 of 543 partici-
pants, with each variant only seen in a single family) expected to
have a pathogenic variant in one of the 56 ACMG genes (but not
limited to ACMG gene-phenotype pairs) recently published by
Lawrence et al. (2014). These authors attributed differences in their
estimates and those published in our prior paper on 1000 partici-
pants (Dorschner et al. 2013) to a variety of factors; however, it
appears that their inclusion of family data, extension of pheno-
types, and differences in classification criteria were the major fac-
tors. First, nearly half of the variants they reported as pathogenic
(13/28) were the second occurrence of a variant in the same family,
with the double counting yielding a higher estimate thanmight be
found in unrelated individuals. Despite 13/14 variants being ob-
served in two participants, none of their families was clearly seg-
Table 5. Classification of six variants by CSER sites
Site
MSH6 c.2731C > T;
p.Arg911*
FBN1 c.4270C > G;
p.Pro1424Ala
TNNT2 c.732G > T;
p.Glu244Asp
RYR1 c.1840C > T;
p.Arg614Cys
LDLR c.967G > A;
p.Gly323Ser
TSC2 c.736A > G;
p.Thr246Ala
1a Pathogenic VUS VUS Likely pathogenic VUS VUS
2 Pathogenic Likely pathogenic/VUSb VUS Pathogenic VUS VUS
3 Pathogenic VUS VUS Pathogenic VUS VUS
4 Pathogenic VUS Likely pathogenic Pathogenic VUS VUS
5 Pathogenic Likely pathogenic/VUS VUS Likely pathogenic VUS Likely pathogenic
6 Pathogenic Pathogenic/likely
pathogenic
VUS Likely pathogenic Likely pathogenic /VUS Likely pathogenic
aClassification from the EVS review of 6503 participants.
bTwo classifications are listed when two reviewers at a site did not agree.
Figure 1. Variants reviewed and classifications in actionable ACMG and non-ACMG genes: (P)
pathogenic; (LP) likely pathogenic; (VUS) variant of uncertain significance; (LB) likely benign; (EP)
expected pathogenic.
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regating the phenotypes of interest. Second, although the ACMG
suggests gene-disease pairs for highly penetrant actionable disor-
ders, Lawrence et al. (2014) considered a different phenotype than
the ACMG for five of their 14 variants, did not consider MAF,
allowed fewermeiotic segregations to count as evidence, and relied
heavily on functional assays. Interestingly, the participant they
report with a putative pathogenic APOB variant had a normal lipid
profile. As the authors note, we classified three of their putative
pathogenic variants as VUSs. Of these, SCN5A T220I is also clas-
sified by Partners LMM as a VUS. Also, CACNA1S T1354S was seen
48 times in the 6503 EVS participants, yet the relevant disorder,
malignant hyperthermia, would be expected in only one person in
this cohort; this variant therefore was reclassified as benign for this
phenotype by the NIH ClinSeq project (Gonsalves et al. 2013), de-
spite abnormal in vitro function (Pirone et al. 2010). These lines of
evidence suggest that the Lawrence et al. (2014) publication over-
estimates IFs. Further, it appears that the phenotypes considered and
their classification criteria, not deeper exome coverage, are the
critical factors contributing to their higher estimate.
The larger sample reported here confirms the deficiency of lit-
erature-derived HGMD pathogenic variants in those of African
versus European ancestry that we previously reported (Dorschner
et al. 2013). This deficit occurs in the
portion of variants identified from the
literature (summarized in HGMD) rather
than in novel disruptive variants in which
the proportion of variants identified in
African-ancestry and European-ancestry
individuals was the same. This is likely
due to the underrepresentation of in-
dividuals of African ancestry in the lit-
erature or databases.
Evenwith clear criteria, there appears
to be substantial inter-reviewer discor-
dance and a bias toward classifying vari-
ants into higher pathogenicity categories.
Discrepancies between any two reviewers
of a variant were common (83/156, 53%).
In the process of adjudication, the final
classification of a variant generally agreed
with the reviewerwho initially assigned it
the lower pathogenicity score. It is possi-
ble that had reviewers each considered
more than 10–15 assigned variants then
review would have become more consis-
tent. High discordance among reviewers
leads to some concern about plans for
crowd-sourced variant classification.
Our findings suggest that discordant
classification can be overcome by using
multiple data sources and many experts
providing input. Indeed, we had 100%
concordance of our final variant classifi-
cations with the SCRP (N = 45) and 98%
concordance with the Partners LMM (N =
99). Additionally, despite use of different
criteria, the most common classifications
made by the CSER laboratories also
matched our classifications.
The criteria for pathogenicity classi-
fication should be standardized across
laboratories in a way that promotes con-
sistent determinations. A new ACMG classification proposal has
been presented and is under internal review; however, this was
unavailable when the University of Washington Return of Results
Committee (RORC) began, and we opted for a simpler system that
worked well, but that might have been improved by the consid-
eration of in silico data. We consider six lines of evidence to be
most important for variant classification:
1. Population minor allele frequency was a useful factor for
variant classification, and variants observed only once in EVS
were most likely to be pathogenic, supporting inclusion of
MAF in classification criteria (Table 2). MAF is used by most
classification systems (Duzkale et al. 2013; Eggington et al.
2013; Thompson et al. 2014) and by the ACMG draft guide-
lines. Highly penetrant alleles should be considerably less
common than the associated dominantly inherited disorder,
particularly as most disorders have high allelic heterogeneity.
In general, high allele frequency in any ancestry group is
evidence against pathogenicity, particularly for dominant
disorders; however, founder mutations in populations with
a high incidence of the associated disorder should be taken
into account.
Figure 2. GERP versus CADD scores of pathogenic, likely pathogenic, and likely benign nondisruptive
variants for dominant disorders. Likely benign variants with a GERP score of less than 1.0 are shown
with their corresponding CADD scores along the 1 x-axis. Their true coordinates are (GERP, CADD):
(7.77, 0.15), (7.34, 0.00), (5.43, 1.93), (4.01, 11.16), (2.76, 8.66), (2.25, 0.66).
Table 6. GERP and CADD scores for nondisruptive variants by classification
Score
(Min, Max) Likely benign VUS
Likely
pathogenic Pathogenic
N 136 405 32 17
GERP++ 3.44 (7.77, 6.08) 3.26 (11.3, 6.17) 4.33 (0.633, 6.04) 4.49 (2.95, 5.67)




2. Although we did not use in silico pathogenicity scores, we find
that lower conservation scores may be of utility in categorizing
variant pathogenicity. In these data, variants classified as
pathogenic had GERP > 2.95 or CADD > 12.37, but high GERP
and CADD scores were seen across all variant classification
categories. Using a GERP < 2 as a criterion to lower the patho-
genicity assignment for nondisruptive variants by one level
would result in two of 32 likely pathogenic variants being
reclassified as variants of uncertain significance, and 84 variants
classified as uncertain significancewould be reclassified as likely
benign. Variants with higher in silico prediction scores would be
more likely to be published and thus cited in HGMD; therefore,
our analysis does not suggest that the high scores are unreliable,
but that when taken in context of published literature, those
with high scores may not be as helpful as low scores in identi-
fying false positive reports of pathogenicity. In silico algorithms,
particularly measures of evolutionary conservation, are consid-
ered in several other classification systems (Duzkale et al. 2013;
Eggington et al. 2013; Thompson et al. 2014). However, the
numerous tools can yield disparate results for any one variant.
3. Cosegregation of variant and disorder within families is useful
for variant classification, but needs to be carefully defined. One
reason for a discordant CSER laboratory classification was dif-
fering weighting of cosegregation data reported in the litera-
ture. To address this, the statistic for defining cosegregation in
a pedigree should be established. The probability of variant
sharing in the pedigree (e.g., one-half for an affected parent-
child pair) is a simple number to compute and interpret. The
odds ratio is simply 1 divided by that probability (2 for an af-
fected parent-child pair), and the LOD score is the log base 10 of
the odds ratio (0.3 for that pair). All of these numbers can be
computed acrossmultiple families with equal ease and, of these,
the probability stated as a fraction is most intuitive. We found
that computation of probability can vary if reviewers do not
consider lack of the variant of interest in unaffected individuals
in their cosegregation evidence and whether adjustments are
made for incomplete or age-dependent penetrance. There is
some disagreement regarding the level of cosegregation that
should be considered evidence for pathogenicity. In this con-
text, it is important to acknowledge that we are not mapping
genes with a small prior probability of being at one specific site
on the genome, for which a LOD score of 3 or 3.3 would be
a usual criterion. Instead, we know the location of our genes of
interest, though there may be dozens of genes of interest for
a cardiomyopathy and only one for some disorders. For this
reason a lower threshold is likely warranted. The NextMedicine
RORC somewhat arbitrarily selected a probability of 1/16, due
to its proximity to a P-value of 0.05. Others have suggested
lower (Thompson et al. 2014) or higher thresholds (Duzkale
et al. 2013; Eggington et al. 2013). Whatever threshold can be
agreed on, we support the need to have a second line of evi-
dence that supports pathogenicity in addition to cosegregation
in a single family. This is because it is possible, though generally
unlikely in the era of full coding sequencing, to have the correct
gene segregating with disease but to have missed the true
pathogenic variant and instead identified a benign variant in
cis. Therefore, in addition to quantifying segregation, addi-
tional variant-specific evidence is needed.
4. Co-occurrence of variant with disorder is a well-accepted crite-
rion that can be identified by careful case-control studies for
more common variants. However, this evidence can be
misapplied by comparing data from two studies, which should
be done with great caution. Additionally, variants common
enough to have been tested in a case-control study are often not
highly penetrant. For very rare variants, statistically significant
case-control comparisons will be unavailable. We looked for
three or more affected unrelated individuals with a variant as
a major component of our evidence criteria, in agreement with
the criteria proposed for classifying incidental findings in 61
genes associated with cardiomyopathy and arrhythmia (Ng
et al. 2013). However, we recognize that others could suggest
higher or lower thresholds, depending on the desired positive
predictive value and sensitivity.
5. Novel or very rare truncation variants expected to lead to
nonsense-mediated decay and loss of canonical splice sites,
when haploinsufficiency is known to cause the associated dis-
order, can be considered to be highly predictive of pathoge-
nicity. This prediction can be confounded by a number of
issues. For example, the truncation variants at the 39 end of the
genemaynot be subject to nonsense-medicated decay, and thus
may not cause the same phenotype as haploinsufficiency.
Therefore, we excluded such variants. However, the exact lo-
cation no longer susceptible to nonsense-mediated decay is
likely to be gene specific and will depend on which exons are
transcribed. As noted elsewhere, noncanonical splice site vari-
ants may require mRNA testing to determine if missplicing
occurs and at what rate (Eggington et al. 2013).
6. A de novo mutation in an individual with a de novo disorder is
evidence of pathogenicity as acknowledged by others (Duzkale
et al. 2013). However, these data are rare in the literature and it
is important to prove parentage when concluding that any
variant is de novo (Biesecker 2012).
Other considerations have been proposed. We did not con-
sider functional data, such as in vitro assays. We do recognize that
some evidence can be very predictive. It is critical to use evidence
from functional assays that are highly correlated with the associ-
ated disorder (MacArthur et al. 2014) and sufficiently validated
with known variants. These assays are not widely available and we
believed that their inclusion in our criteria would lead to poor and
inconsistent classifications. The development and cataloging of
reliable assays should be a high priority for our field. Myriad Ge-
netics, Inc. considers ‘‘history weighting’’ data (Eggington et al.
2013). This considers that patients with true mutations should
have the disorder in their families, even in the absence of coseg-
regation data. Similarly, Myriad Genetics and others (Duzkale et al.
2013) consider that, for a dominant disorder, when a variant is
seen in trans with a known pathogenic variant in an affected per-
son, that is evidence against pathogenicity. Finally, expert data-
bases are considered by some. We did accept Myriad BRCA1 and
BRCA2 variant classifications because they have a large amount of
data that is not public. However, when possible, evaluation of the
primary data supporting the variant classification is optimal.
An important limitation of our study is our inability to assess
if the participants were ascertained based on phenotypes that
enriched for any of the pathogenic or likely pathogenic variants
identified. This might lead to an overestimate of the frequency of
such IFs. Of most concern, several cohorts were enriched for lipid
disorders, vascular disease, or chronic obstructive lung disease.
This could have led to enrichment in LDLR and SERPINA1 patho-
genic variants. However, we do not see a marked excess in patho-
genic or likely pathogenic variants in these genes, considering that
the population frequencies of these disorders in participants of
European ancestry are 1/500 for familial hypercholesterolemia and
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between 1/500 and 1/3500 for alpha-1-antitrypsin deficiency
(Rader et al. 2003; Kircher et al. 2014). Similarly, the number of
variants classified as pathogenic or likely pathogenic for disorders
expected to be at usual population frequencies were in the expected
range, supporting the classifications for variants in genes such as
BRCA1or BRCA2 and those for Lynch syndrome (Janavicius 2010;
Hampel and de la Chapelle 2011), expected to be found in 1/350 to
1/1000 people.
A second limitation is that some pathogenic variants may
have been missed due to incomplete exome coverage or our in-
ability to consider indels. However, as seen in Supplemental Table
5, only six genes associated with dominant disorders and two
genes associated with recessive disorders had less than eightfold
coverage of 90% of the coding regions. Indels and copy number
variants (CNVs) may be missed in our analyses due to limitations
in calling these types of variants by the exome sequencing shorter
read length (50 base pairs) technology used when the ESP data was
generated. However, indels and CNVs are not known to comprise
a large portion of the known pathogenic variants for most
disorder-gene pairs considered.
A third limitation is that this estimate of the frequency of IFs
expected to be returned from exome sequencing resultsmaynot be
generalizable to other ethnic groups or to children. We only con-
sidered gene-disease pairs in which the disorder could remain
undiagnosed in adulthood. The addition of genes associated with
disorders that would manifest before adulthood might result in
more returned results.
A fourth limitation is the use of HGMD to identify potential
pathogenic variants for review. It is possible that a small number of
known pathogenic or likely pathogenic variants exist in the EVS
that have not been published and thus would not be contained in
the HGMD database. However, in the absence of a HGMD entry, it
is unlikely enough data would be available for other than a VUS
classification. The review of all expected disruptive variants also
decreased this likelihood.
With regard to returning these results to the ESP participants,
the primary authors do not have access to these cohorts. However,
each cohort can address return separately. A substantial proportion
of the sample contributing to the ESP included participants from
one of six NHLBI cohorts in the HeartGO Consortium, including
the Multi-Ethnic Study of Atherosclerosis (MESA), Framingham
Heart Study, and Jackson Heart Study. Many participants in these
cohorts provided consent to be recontacted for return of action-
able genetic research results. Findings from the current study will
inform future plans for return of results to consenting research
participants.
In summary, we find that ;2.0% of adults of European an-
cestry and 1.1% of adults of African ancestry can be expected to
have actionable highly penetrant pathogenic or likely pathogenic
SNVs identified by exome sequencing at this time. These estimates
are reduced to 1.6% and 1.0% for pathogenic or likely pathogenic
variants in genes for which the ACMG recommends review and
return of IFs to adults. Individuals of Ashkenazi ancestry are
expected to have a higher rate of pathogenic variants due to founder
mutations alone (Hartge et al. 1999). In addition, reviewers are likely
to be inconsistent in their categorizations and biased toward more
pathogenic categories. This suggests the need for simple, consistent
criteria for classifying variant pathogenicity and improved variant-
specific databases and knowledge bases. Finally, current literature
identifies fewer pathogenic variants in those of African ancestry,
likely due to the underrepresentation of these individuals in clin-
ical and research studies.
Methods
Gene list development
The list of 112 actionable genes paired with diseases was agreed
upon unanimously by the University of Washington National
Human Genome Research Institute (NHGRI)-funded CSER ‘‘NEXT
Medicine study’’ RORC; this committee, its membership, and
process are detailed elsewhere (Dorschner et al. 2013). ‘‘Action-
able’’ genes in adults were defined as having deleterious variant(s)
whose penetrance would result in specific, defined medical
recommendation(s) that are supported by evidence, the imple-
mentation of which would be expected to avoid significant mor-
bidity andmortality. The benefit of interventionmust be sufficient
to counter any anxieties raised by the identification of an un-
expected predisposition to a disorder. The University of Wash-
ington NEXT Medicine study is developing an actionable variant
database for an adult population, and the EVS has ESP cohorts that
were largely adults at the time of recruitment, and thus, may ex-
clude subjects with pediatric disorders. For these reasons, only
gene-disorder pairs that might remain undiagnosed in adulthood
were included. The list of genes determined to date to have ac-
tionable variants has been previously published (Berg et al. 2013;
Dorschner et al. 2013) and is continually updated as new and
putative gene-disease associations are reviewed. Since the publi-
cation of Dorschner et al. (2013), three genes have been added to
the list (MAX, TGFB2, and TMEM127) and five genes have been
removed: (GPD1L, HCN4, KCNE3, SCN1B, and SCN3B). These five
genes were removed based on RORC consensus that the evidence
to support the gene-disease association did not reach the threshold
for inclusion. The list of actionable genes is likely to grow as evi-
dence for novel genes accumulates; however, it is likely that further
genes will be rarer and rarer causes of disease and therefore a source
of IFs. The full list of gene-disease pairs along with the percentage
of each gene’s coding region covered by the ESP sequencing
technology is in Supplemental Table 5.
Criteria for classification of variants
Given that we are addressing potential IFs, our criteria for the
classification of highly penetrant pathogenic variants (Table 1A,B)
were stringent. Each variant from HGMD was classified as ‘‘path-
ogenic,’’ ‘‘likely pathogenic,’’ ‘‘variant of uncertain significance’’
(VUS), or ‘‘likely benign.’’ Additionally, we defined ‘‘disruptive’’
expected pathogenic variants as truncating and missplice-causing
variants not identified by HGMD as disease causing. We did not
assign variants to the ‘‘benign’’ category, as all variants selected for
review were either listed as disease-causing variants in HGMD or
were disruptive SNVs (predicted to cause a premature termination
or missplice). Finally, we accepted Myriad BRCA1 and BRCA2 var-
iant classifications that were known to us because their classifica-
tions use data that are not available.
Multiple sources of data were evaluated to classify the path-
ogenicity of each variant. Ancestry-specific allele frequencies from
the EVS were used to exclude variants that were too common to be
highly penetrant pathogenic variants for the relevant disorder,
based on the prevalence of the disorder. The references cited by
HGMD Professional 2013.3 (Stenson et al. 2009), PubMed, and
Google were evaluated. Additional supporting references for each
variant were searched for in other databases, including the Leiden
Open Variant Databases (LOVD), ClinVar, and InSiGHT, and these
references were also reviewed. Variants in some of the genes of
interest were also associated with disorders that were not consid-
ered highly actionable (e.g., RYR1 may be associated with neuro-




hyperthermia), or their association with disease was not estab-
lished to our required evidence level. Only variants putatively
producing the phenotype of interest were considered pathogenic.
Participants and variant selection
The NHLBI ESP has 6503 participants whose variants are summa-
rized on the EVS. We had previously evaluated variants in 1000
participants (500 European ancestry and 500 African ancestry) and
now have evaluated variants in the remaining 5503 participants.
These variant annotations were derived from accessing the ESP
database on November 7, 2013, using the EVS version v.0.0.22.We
pooled these data to improve ancestry-specific estimates. ESP
participants are from 18 cohorts with heart, lung, and blood
phenotypes. Further details regarding these phenotypes are avail-
able on the ESP website (http://evs.gs.washington.edu/EVS/). The
sequence data from this study have been submitted to the NCBI
database of Genotypes and Phenotypes (dbGaP; http://www.ncbi.
nlm.nih.gov/dbgap) under accession numbers phs000254.v2.p1,
phs000279.v2.p1, phs000281.v5.p3, phs000290.v1.p1, phs000291.
v2.p1, phs000296.v3.p2, phs000327.v1.p1, phs000334.v1.p1,
phs000347.v1.p1, phs000362.v1.p1, phs000398.v2.p1, phs000399.
v1.p2, phs000400.v3.p1, phs000401.v7.p9, phs000402.v2.p1,
phs000403.v3.p3, phs000422.v1.p1, phs000518.v1.p1, phs000546.
v1.p1, phs000556.v1.p1, phs000581.v1.p1, phs000582.v1.p1,
phs000587.v1.p1, and phs000632.v1.p1.
Ancestry was inferred from analysis of principal components
(Patterson et al. 2006; Price et al. 2006). It has been previously
reported that;3.2% of the entire cohort of 6503 participants have
Ashkenazi ancestry (Dorschner et al. 2013). All of these 6503 par-
ticipants’ exome variants were reviewed for the 112 genes paired
with phenotypes of interest (so that the initial 1000 participants
were investigated for variants in the three new genes) for any SNV
listed as disease causing in HGMD and any disruptive expected
pathogenic variants. Indels were not included due to difficulty of
accurately calling these with the shorter read length used in gen-
erating the ESP sequence data. Variants with a MAF greater than
0.005 in genes associatedwith autosomal dominant disorders were
not evaluated as they were too common to be considered a highly
penetrant pathogenic variant for a dominant disorder given the
frequencies of the disorders under consideration. This is the same
allele frequency used as a threshold by the International Society for
Gastroenterology and Hereditary Tumors (InSiGHT) (Thompson
et al. 2014). We did not eliminate the possibility of low penetrance
pathogenic variants with MAF > 0.005. A single reviewer classified
20 variants with MAF < 0.005, but with 10 or more occurrences in
EVS (MAF ;0.0008). Variants for disorders inherited in an auto-
somal recessive pattern were reviewed regardless of MAF, but only
when a single participant had two potentially pathogenic variants,
each annotated in HGMD or considered disruptive. We assumed
that the recessive variants were carried on separate alleles, in trans,
as this is more likely than the variants being in cis. Carrier status
was not assessed in this study.
Expert variant review of EVS variants
Each of 52 expert reviewers considered a subset of all potential
pathogenic variants. All reviewers were geneticists or reviewed
with a geneticist partner: 48 were clinical geneticists, genetic
counselors, or molecular geneticists, and the remainder had sig-
nificant relevant genomic expertise. Each reviewer was provided
an Excel spreadsheet with detailed information on the 10–15
variants assigned to them for classification and links to publica-
tions cited in HGMD. They were each asked to determine whether
the allele frequency was less than a disease-specific maximum
frequency (DAF) and to review the primary literature and databases
to document these data and to determine if the evidence met the
pathogenicity criteria (Table 1A,B). Reviewers were instructed to
calculate the maximum allowable allele frequencies for each dis-
order under a conservativemodel, which included the assumption
that the given disorder was wholly due to that variant considering
the mode of inheritance of the disorder. When disorder frequen-
cies were unknown, reviewers were asked to conservatively over-
estimate. Reviewers were provided with total minor allele frequency
and ancestry-specific allele frequencies from EVS and from the 1000
Genomes Project data (Brownstein et al. 2014) for each variant.
Reviewers were instructed to ignore the first occurrence of the
variant when considering the EVS derived MAF, because all SNVs
were ascertained from the EVS, biasing the MAF upward. We did
not have EVS identifiers or phenotypes, so that genotype–phe-
notype correlation was not possible. Reviewers were trained on all
aspects of review by an in-person conference or a videoconfer-
ence, and a YouTube training video was available for reference at
all times (https://www.youtube.com/watch?v=fa01IZzNc20). The
training video file can also be accessed in the Supplemental Ma-
terial. A genetic counselor was available at all times to answer
questions, and articles that reviewers could not locate were pro-
vided to them.
Each reviewer filled out a spreadsheet that summarized the
findings relevant to the pathogenicity categorization; these data
were reviewed by a genetic counselor to ensure that the classifi-
cation matched the evidence summarized by the reviewer. Re-
viewers recorded the time inminutes it took to review each variant
andwere asked to nominate very difficult-to-categorize variants for
committee review.
Classification of non-HGMD disruptive variants
Any variants in the first 90% of the predicted amino acid se-
quence that were not listed in HGMD as disease-causing vari-
ants but may introduce a premature termination codon directly
or as a result of 61,2 splice site variant were also evaluated. We
did not include variants at the 39 end of the gene that met the
‘‘position-of-an-exon-exon-junction’’ rule of being <50 nucle-
otides from the final exon–exon junction to be expected to es-
cape nonsense-mediated decay of the mRNA (Maquat 2004;
Conti and Izaurralde 2005) and result in functional protein
products, albeit sometimes pathogenic products (Isidor et al.
2011). We reviewed whether truncating variants were reported
to cause the disorder of interest. Literature, ClinVar, and other
relevant databases were reviewed to search for prior reports of
these variants. In rare cases, available expert knowledge of the
pathogenic variant spectrum for certain genes and disorders was
also taken into account.
Classification quality control
For quality control, initially 25% (156/615) of the variants were
also examined for pathogenicity by a second reviewer, blinded to
the first review. Discordant classifications were reanalyzed by an
experienced third reviewer. Discordance between reviewers was
evaluated in a number of ways, including comparison of reviewers
who had participated in the prior analysis (Dorschner et al. 2013)
and those who had not. Several reviewers made systematic errors,
such as including EVS participants with unknown phenotype as
affected with the disorder; such variants were reclassified by a
second, experienced reviewer. Additionally, tominimize erroneous
classifications, all variants that were initially classified as patho-
genic or likely pathogenic were evaluated by a second, experienced
reviewer.
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Comparison with other variant classification systems
All variant classifications from the initial 1000 ESP participants
and from the remaining 5503 ESP participants with aMAF <0.0008
(n = 595) were compared to classifications by the Partners LMM
(http://personalizedmedicine.partners.org/Laboratory-For-Molecular-
Medicine/Default.aspx) and collected through the SCRP (http://
sharingclinicalreports.org/). In addition, six variants were randomly
selected within groups of varying pathogenicity assignments and
were classified blindly by five research and clinical laboratories within
theCSER consortium (http://www.genome.gov/27546194) according
to their routine laboratory procedures.
Evaluation of pathogenicity measures
We evaluated two measures of predicted pathogenicity, GERP mam-
malian conservation scores and the CADD summary score of con-
servation, substitution, and regulation (Cooper et al. 2005; Davydov
et al. 2010; Kircher et al. 2014), to determine if these scores were
correlated with pathogenicity classification. Scores for nondisruptive
variants in genes associated with dominant and recessive disor-
ders were compared across pathogenicity assignments. These
measures were not used as part of our classification criteria, which
allowed us to assess their utility in predicting classification.
Statistical analyses
One-sided binomial tests were used to evaluate whether variants
seen only once, versus those seen more than once, were seen in
excess among 64 pathogenic or likely pathogenic variants in genes
associated with dominant disorders. Disruptive variants not listed
as disease causing in HGMDwere excluded from this exercise. The
null hypothesis that the MAF of each variant was independent of
pathogenic, likely pathogenic, and variant of uncertain signifi-
cance (VUS) classifications was tested using an analysis of variance
(ANOVA). We excluded the likely benign class from this test, as
many variants were placed in this class due to their highMAF. This
test considered only variants in genes associated with dominantly
inherited disorders, given that variants in genes associated with
disorders with a recessive inheritance pattern would have different
MAF ranges. Further, this test considered the higher ancestry-
specific MAF for each variant because a higher MAF in either
population would be considered evidence of a benign variant.
Data access
All 626 variant annotations have been submitted to the NCBI
ClinVar (http://www.ncbi.nlm.nih.gov/clinvar) under submitter
name CSER_CC_NCGL.
List of affiliations
1Department of Medicine, Division of Medical Genetics, Univer-
sity ofWashington, Seattle,Washington 98195, USA; 2Department
of Genome Sciences, University of Washington, Seattle, Wash-
ington 98195, USA; 3Department of Laboratory Medicine, Uni-
versity of Washington, Seattle, Washington 98195, USA; 4De-
partment of Psychiatry and Behavioral Sciences, University of
Washington, Seattle, Washington 98195, USA; 5Department of
Pathology, University of Washington, Seattle, Washington 98195,
USA; 6Department of Pediatrics, University ofWashington, Seattle,
Washington 98195, USA; 7Department of Pediatrics, Division of
Genetic Medicine, University of Washington, Seattle, Washington
98195, USA; 8Department of Genetics, The Children’s Hospital
of Philadelphia, Philadelphia, Pennsylvania 19104, USA; 9De-
partment of Pathology and Laboratory Medicine, The Children’s
Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA;
10The Framingham Heart Study, Division of Intramural Research,
National Heart, Lung and Blood Institute, Framingham, Massa-
chusetts 01702, USA; 11Department of Pathology and Laboratory
Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
19104, USA; 12Department of Pediatrics, Division of Human Ge-
netics, The Children’s Hospital of Philadelphia, Philadelphia,
Pennsylvania 19104, USA; 13Laboratory of Molecular Medicine,
PartnersHealthcare, Boston,Massachusetts 02115, USA; 14Partners
Healthcare Personalized Medicine, Partners Healthcare, Boston,
Massachusetts 02115, USA; 15Department of Genetics, The Uni-
versity of North Carolina at Chapel Hill, Chapel Hill, North Car-
olina 27599, USA; 16Translational Genomics and Population Sci-
ences, Los Angeles Biomedical Research Institute and Department
of Pediatrics at Harbor-UCLA, Torrence, California 90502, USA;
17Department of Pathology and Laboratory Medicine, The Uni-
versity of North Carolina at Chapel Hill, Chapel Hill, North Car-
olina 27514, USA; 18Department of Cancer Genetics, University of
Texas Southwestern Medical Center, Dallas, Texas 75390, USA;
19Medical Genetics Research Institute, Cedars-Sinai Medical Cen-
ter, Los Angeles, California 90048, USA; 20Department of Pathol-
ogy, Brigham and Women’s Hospital, Boston, Massachusetts
02115, USA; 21Department of Pathology, Harvard Medical School,
Boston, Massachusetts 02115, USA; 22Department of Genetic and
Genomic Medicine, Division of Medical Genetics, Mount Sinai
Hospital, New York, New York 10029, USA; 23Genetic Diseases
Research Branch, National Human Genome Research Institute,
Bethesda, Maryland 20892, USA; 24Cardiac Arrhythmia Service
and Cardiovascular Research Center, Massachusetts General Hos-
pital, Boston, Massachusetts 02114, USA; 25HudsonAlpha Insti-
tute for Biotechnology, Huntsville, Alabama 35806, USA; 26De-
partment of Medical Ethics and Health Policy, University of
Pennsylvania Perelman School of Medicine, Philadelphia, Penn-
sylvania 19104, USA; 27Department of Molecular and Medical
Genetics, OregonHealth and Science University, Portland, Oregon
97239, USA; 28Department of Pediatrics, Division of Infectious
Disease, Los Angeles Biomedical Research Institute and De-
partment of Pediatrics at Harbor-UCLA, Torrence, California
90502, USA; 29Center for Public Health Genomics, University of
Virginia, Charlottesville, Virginia 22908, USA; 30Division of Car-
diology, Massachusetts General Hospital, Boston, Massachusetts
02114, USA; 31Department of Bioethics and Humanities, Univer-
sity of Washington, Seattle, Washington 98195, USA; 32Genetic
Services, Group Health Cooperative, Seattle, Washington 98112,
USA; 33Department of Neurology, University of Washington,
Seattle, Washington 98195, USA; 34Veterans Affairs Puget Sound
Health Care System Geriatric Research, Education, and Clinical
Center, Seattle, Washington 98108, USA; 35Dermatology, Group
Health Cooperative, Seattle, Washington 98112, USA; 36Clinical
Research Division, Fred Hutchinson Cancer Research Center,
Seattle, Washington 98109, USA; 37Department of Medicine, Di-
vision of Gastroenterology, University of Washington, Seattle,
Washington 98195, USA; 38Treuman Katz Center for Pediatric
Bioethics, Seattle Children’s Research Institute, Seattle, Wash-
ington 98105, USA; 39Department of Anesthesiology and Pain
Medicine, University of Washington, Seattle, Washington 98195,
USA; 40Department of Pediatrics, Division of Bioethics, University
of Washington, Seattle, Washington 98195, USA.
Acknowledgments
We thank Joshua Akey for sharing his group’s ancestry analyses.
This work was funded by the NIH, NHGRI/NCI U01HG006507,




U01HG006546, UM1HG007301, UM1HG007292, U01HG006487,
U01HG006492, U41HG006834, U41HG006834, NIH/NIGMS T32
GM007454, 1K23HL114724, 5P30CA015704, BurroughsWellcome
Fund (WMG), and Washington State Life Sciences Discovery Fund
(2065508, to the Northwest Institute of Genetic Medicine). The
authors wish to acknowledge the support of the National Heart,
Lung, and Blood Institute (NHLBI) and the contributions of the
research institutions, study investigators, field staff, and study
participants in creating this resource for biomedical research.
Funding for GO ESP was provided by NHLBI grants RC2
HL-103010 (HeartGO), RC2 HL-102923 (LungGO), and RC2
HL-102924 (WHISP). The exome sequencing was performed
through NHLBI grants RC2 HL-102925 (BroadGO) and RC2
HL-102926 (SeattleGO). Dr. Pritchard is supported by a 2013
Prostate Cancer Foundation Young Investigator Award. The NEXT
Medicine return of results committee included A.M., B.W., B.S.,
C.G., D.N., F.H., G.J., J.P.E., J.K., J.B., K.L., L.A., M.D., M.M., P.B.,
R.B., R.S., S.M.F., T.B., V.S., W.R., W.G., and W.B. The variant re-
viewers were A.J., A.D.J., A.S., B.S., C.G., D.H., D.K., E.R., E.J., E.T.,
F.H., G.J., H.T., J.B., J.R., J.S., J.R., J.K., J.B., J.S., K.F., K.J., K.T., K.C.,
K.L., L.A., L.C., L.K., L.B., L.R., M.T., M.D., M.D., M.M., N.S., O.G.,
P.B., R.H., R.B., R.S., S.L., S.R., S.M., T.W., W.R., W.B., and X.G.
References
American College ofMedical Genetics and Genomics. 2014. ACMG updates
recommendation on ‘‘opt out’’ for genome sequencing return of results.
https://www.acmg.net/docs/Release_ACMGUpdatesRecommendations_
final.pdf.
Berg JS, Amendola LM, Eng C, Van Allen E, Gray SW, Wagle N, Rehm HL,
DeChene ET, Dulik MC, Hisama FM, et al. 2013. Processes and
preliminary outputs for identification of actionable genes as incidental
findings in genomic sequence data in the Clinical Sequencing
Exploratory Research Consortium. Genet Med 15: 860–867.
Biesecker L. 2012. Improving the rigor of mutation reports: biologic
parentage and de novo mutations. Hum Mutat 33: 1501–1502.
Brownstein CA, Beggs AH, Homer N, Merriman B, Yu TW, Flannery KC,
Dechene ET, Towne MC, Savage SK, Price EN, et al. 2014. An
international effort towards developing standards for best practices in
analysis, interpretation and reporting of clinical genome sequencing
results in the CLARITY Challenge. Genome Biol 15: R53.
Conti E, Izaurralde E. 2005. Nonsense-mediated mRNA decay: molecular
insights andmechanistic variations across species.Curr Opin Cell Biol17:
316–325.
Cooper GM, Stone EA, Asimenos G, NISC Comparative Sequencing
Program, Green ED, Batzoglou S, Sidow A. 2005. Distribution and
intensity of constraint in mammalian genomic sequence. Genome Res
15: 901–913.
Davydov EV, Goode DL, Sirota M, Cooper GM, Sidow A, Batzoglou S. 2010.
Identifying a high fraction of the human genome to be under selective
constraint using GERP++. PLoS Comput Biol 6: e1001025.
DorschnerMO, Amendola LM, Turner EH, Robertson PD, Shirts BH, Gallego
CJ, Bennett RL, Jones KL, Tokita MJ, Bennett JT, et al. 2013. Actionable,
pathogenic incidental findings in 1,000 participants’ exomes. Am J Hum
Genet 93: 631–640.
Duzkale H, Shen J, McLaughlin H, Alfares A, Kelly MA, Pugh TJ, Funke BH,
Rehm HL, Lebo MS. 2013. A systematic approach to assessing the
clinical significance of genetic variants. Clin Genet 84: 453–463.
Eggington JM, Bowles KR, Moyes K, Manley S, Esterling L, Sizemore S,
Rosenthal E, Theisen A, Saam J, Arnell C, et al. 2013. A comprehensive
laboratory-based program for classification of variants of uncertain
significance in hereditary cancer genes. Clin Genet 86: 229–237.
Gonsalves SG, Ng D, Johnston JJ, Teer JK, Stenson PD, Cooper DN, Mullikin
JC, Biesecker LG. 2013. Using exome data to identify malignant
hyperthermia susceptibility mutations. Anesthesiology 119: 1043–1053.
Green RC, Berg JS, Grody WW, Kalia SS, Korf BR, Martin CL, McGuire AL,
Nussbaum RL, O’Daniel JM, Ormond KE, et al. 2013. ACMG
recommendations for reporting of incidental findings in clinical exome
and genome sequencing. Genet Med 15: 565–574.
Hampel H, de la Chapelle A. 2011. The search for unaffected individuals
with Lynch syndrome: do the ends justify the means? Cancer Prev Res
(Phila) 4: 1–5.
Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker MA. 1999. The
prevalence of common BRCA1 and BRCA2mutations among Ashkenazi
Jews. Am J Hum Genet 64: 963–970.
Isidor B, Lindenbaum P, Pichon O, Bezieau S, Dina C, Jacquemont S,Martin-
Coignard D, Thauvin-Robinet C, Le Merrer M, Mandel JL, et al. 2011.
Truncating mutations in the last exon of NOTCH2 cause a rare skeletal
disorder with osteoporosis. Nat Genet 43: 306–308.
Janavicius R. 2010. Founder BRCA1/2mutations in the Europe: implications
for hereditary breast-ovarian cancer prevention and control. EPMA J 1:
397–412.
Johnston JJ, RubinsteinWS, Facio FM, Ng D, Singh LN, Teer JK, Mullikin JC,
Biesecker LG. 2012. Secondary variants in individuals undergoing
exome sequencing: screening of 572 individuals identifies high-
penetrance mutations in cancer-susceptibility genes. Am J Hum Genet
91: 97–108.
Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. 2014. A
general framework for estimating the relative pathogenicity of human
genetic variants. Nat Genet 46: 310–315.
Lawrence L, Sincan M, Markello T, Adams DR, Gill F, Godfrey R, Golas G,
Groden C, Landis D, Nehrebecky M, et al. 2014. The implications of
familial incidental findings from exome sequencing: the NIH
Undiagnosed Diseases Program experience. Genet Med 16: 741–750.
MacArthur DG, Manolio TA, Dimmock DP, Rehm HL, Shendure J, Abecasis
GR, Adams DR, Altman RB, Antonarakis SE, Ashley EA, et al. 2014.
Guidelines for investigating causality of sequence variants in human
disease. Nature 508: 469–476.
Maquat LE. 2004. Nonsense-mediated mRNA decay: splicing, translation
and mRNP dynamics. Nat Rev Mol Cell Biol 5: 89–99.
Ng D, Johnston JJ, Teer JK, Singh LN, Peller LC, Wynter JS, Lewis KL,
Cooper DN, Stenson PD, Mullikin JC, et al. 2013. Interpreting
secondary cardiac disease variants in an exome cohort. Circ Cardiovasc
Genet 6: 337–346.
Patterson N, Price AL, Reich D. 2006. Population structure and
eigenanalysis. PLoS Genet 2: e190.
Pirone A, Schredelseker J, Tuluc P, Gravino E, Fortunato G, Flucher BE,
Carsana A, Salvatore F, Grabner M. 2010. Identification and functional
characterization of malignant hyperthermia mutation T1354S in the
outer pore of the Cava1S-subunit. Am J Physiol Cell Physiol 299: C1345–
C1354.
Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D.
2006. Principal components analysis corrects for stratification in
genome-wide association studies. Nat Genet 38: 904–909.
Rader DJ, Cohen J, Hobbs HH. 2003.Monogenic hypercholesterolemia: new
insights in pathogenesis and treatment. J Clin Invest 111: 1795–1803.
Stenson PD, Mort M, Ball EV, Howells K, Phillips AD, Thomas NS, Cooper
DN. 2009. The Human Gene Mutation Database: 2008 update. Genome
Med 1: 13.
Thompson BA, Spurdle AB, Plazzer JP, Greenblatt MS, Akagi K, Al-Mulla F,
Bapat B, Bernstein I, Capella G, den Dunnen JT, et al. 2014. Application
of a 5-tiered scheme for standardized classification of 2,360 unique
mismatch repair gene variants in the InSiGHT locus-specific database.
Nat Genet 46: 107–115.
Received August 27, 2014; accepted in revised form December 10, 2014.
Actionable incidental findings in 6503 participants
Genome Research 315
www.genome.org
